Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

85.00 +0.08 (+0.10%)
Streaming Delayed Price Updated: 11:08 AM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
How To Attend Incyte Q1 2022 Earnings Conference Call
Incyte (NASDAQ:INCY) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Incyte (INCY) Conference Call Follow this link to access the live... 
Via Benzinga
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
This Favorable Sign Appears On Incyte's Chart
If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland
The  
Via Benzinga
Expert Ratings For Incyte
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Are Incyte Shares Trading Lower Today?
Incyte Corporation's (NASDAQ: INCY)  
Via Benzinga
Recap: Incyte Q4 Earnings
  Incyte (NASDAQ:INCY) reported its Q4 earnings results on Tuesday, February 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder
Incyte Corporation (NASDAQ: INCY)  
Via Benzinga
Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks
At the American Academy of Dermatology Annual Meeting, Eli Lilly And Co (NYSE: LLY) and Incyte Corp (NASDAQ: INCY)  
Via Benzinga
Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
From Incyte
Via Business Wire
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
FDA Extends Decision Date For Incyte's Ruxolitinib In Vitiligo Skin Disorder
The FDA has extended the review period for Incyte Corporation's (NASDAQ: INCY) supplemental application for ruxolitinib cream (Opzelura) for vitiligo... 
Via Benzinga
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
From Incyte Corporation
Via Business Wire
Insiders Buy More Than $80M Of 3 Stocks
Although US stock futures traded higher this morning on Friday, there were a few notable insider trades. 
Via Benzinga
Why Are Company Insiders Buying These 7 S&P 500 Stocks?
Most investors are likely familiar with the adage, "actions speak louder than words." That saying certainly applies to the executives and other corporate insiders buying... 
Via Benzinga
Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients
According to a British study, Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) Olumiant (baricitinib) reduced the risk of death in... 
Via Benzinga
CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval
The FDA approved CTI BioPharma Corp's (NASDAQ: CTIC) Vonjo (pacritinib) for treating adult patients with myelofibrosis, a type of bone marrow cancer with low... 
Via Benzinga
Insiders Buying Incyte And 2 More Stocks
Although U.S. stock futures traded higher this morning after recording losses on Tuesday, there were a few notable insider trades. When i... 
Via Benzinga
7 Insider Stocks to Buy as Execs Snap Them Up
With equity prices soaring to record levels, many execs have cashed out. Here are the insider stocks where execs are cashing in. 
Via InvestorPlace
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Insiders Buy Around $112M Of 3 Stocks
US stock futures traded higher on Tuesday, amid reports that some Russian troops are returning to their bases. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Oncolytics Announced Updates On Clinical Trials Of New Treatment For Triple-Negative Metastatic Breast Cancer
Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022
Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
From Incyte Corporation
Via Business Wire
Bear Market Bets In Biotech
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
Earnings Scheduled For February 8, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.